Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRVg versus Verorab for post-exposure rabies vaccination
2015-005194-20Phase 3
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of rabies virus inactivated antigen, A and Purified Vero cell rabies vaccine in rabies (2 arms), sponsored by Sanofi. Primary endpoint: Proportion of subjects with RVNA titer at least 0.5 IU/mL at Day 14.
02
Drugs
rabies virus inactivated antigen, APurified Vero cell rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on 2015-005194-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005194-20.